Medication info
Empagliflozin and Metformin Prolonged Release Tablet 10/1000 mg

Empagliflozin and Metformin Prolonged Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White and light yellow, double-sided, convex oval prolonged-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202402211 · Approved 2024.09.11 · Insurance code 645907580

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: 25mg of empagliflozin and 2000 mg of extended-release metformin hydrochloride. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet once daily of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine should be swallowed whole and not split, crushed, ground, or chewed. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). Special Populations Renal impairment As dose adjustment based on renal function is required, assessment of renal function is recommended before and periodically during treatment with this medicine. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], if the medicine is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used by adjusting the dose of metformin hydrochloride as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) to below 45 ml/min/1.73m2, this medicine should be discontinued immediately. Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood glucose control in adult patients with type 2 diabetes by combining empagliflozin with metformin. It is administered as an adjunct to dietary and exercise measures in patients where these alone do not provide sufficient glycemic control. Additionally, caution is advised in patients with concurrent cardiovascular disease due to the potential for cardiovascular events, and consultation with a specialist is recommended. This medication improves blood glucose control and aids in the treatment of diabetes.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: 25mg of empagliflozin and 2000 mg of extended-release metformin hydrochloride. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet once daily of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine should be swallowed whole and not split, crushed, ground, or chewed. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). Special Populations Renal impairment As dose adjustment based on renal function is required, assessment of renal function is recommended before and periodically during treatment with this medicine. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], if the medicine is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used by adjusting the dose of metformin hydrochloride as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) to below 45 ml/min/1.73m2, this medicine should be discontinued immediately. Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is used for the treatment of type 2 diabetes and helps to control blood sugar levels. Before taking this medication, kidney function should be assessed, and it should not be used if renal function is severely impaired. Patients in acute conditions such as severe infections, dehydration, acute myocardial infarction, or heart failure should also refrain from using this medication for safety reasons. There is a risk of hypoglycemia when used concurrently with insulin or sulfonylureas, so caution is necessary. This medication can cause a rare but serious side effect known as lactic acidosis, and if symptoms such as vomiting, abdominal pain, malaise, or difficulty breathing occur, it is important to consult a doctor immediately. Urinary tract infections and genital infections may occur, so prompt treatment is necessary if signs of infection appear. This medication can cause decreased fluid volume, leading to dehydration symptoms or low blood pressure, so water intake should be monitored. Patients with liver function issues or excessive alcohol consumption should avoid using this medication. Women who are pregnant or may become pregnant should not take this medication, and breastfeeding should be discontinued while on this medication. Elderly patients may have an increased risk of kidney function impairment, so regular kidney function monitoring is necessary, and there is also a higher risk of hypoglycemia. This medication should be swallowed whole and not chewed or broken into pieces; it is normal for the tablet coating to appear in the stool. Before undergoing surgery or imaging tests involving iodinated contrast agents, this medication should be paused for a certain period, and resuming should occur after renal function recovery. There may be interactions with other medications, so it is crucial to inform the physician or pharmacist of any other medications being taken. In case of overdose, serious side effects may occur; therefore, immediate medical attention is required. If any unusual symptoms or discomfort arise during treatment, it is important to consult healthcare professionals immediately.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of Vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 172 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • gastrointestinal bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorders
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • orthostatic dizziness
  • sensory loss
  • drowsiness
  • facial paralysis
  • memory disturbance
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • fatigue
  • peripheral edema
  • facial edema
  • fever
  • chills
  • strange sensations
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urine retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • next-day symptoms
  • diabetes mellitus
  • hyperlipidemia
  • hyponatremia
  • Vitamin D deficiency
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • circular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • back pain
  • limb pain
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • ocular congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exercise-induced dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • epistaxis
  • allergic rhinitis
  • limb injuries
  • skin lacerations
  • contusions
  • rib fractures
  • concussion
  • corneal abrasion
  • falls
  • hand fractures
  • iliotibial band syndrome
  • open eye injuries
  • pelvic fractures
  • road traffic accidents
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • gallstones
  • hepatitis
  • ear pain
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to keep it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White and light yellow, double-sided, convex oval prolonged-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.